share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  08/07 07:06
Moomoo AI 已提取核心訊息
Clene Inc., a clinical-stage pharmaceutical company, reported financial results for the quarter ended June 30, 2024. The company experienced a net loss of $6.785 million, a significant improvement from the $25.143 million loss in the same period the previous year. Basic and diluted net loss per share was $1.06, compared to $5.84 in the prior year. Revenue from product sales and royalties decreased year-on-year, with product revenue dropping from $226,000 to $64,000 and royalty revenue from $43,000 to $27,000. Operating expenses also saw a reduction, with research and development expenses decreasing by 37% to $4.15 million and general and administrative expenses by 16% to $3.314 million. The company's cash, cash equivalents, and marketable securities stood at $21.7 million as of June 30, 2024. Clene Inc. continues to focus on the development of its lead drug candidate, CNM-Au8, for central nervous system disorders. The company has no drugs approved for commercial sale and relies on revenue from dietary supplements and licensing agreements. Clene Inc. has implemented cost-saving measures and is exploring additional funding options to support its operations.
Clene Inc., a clinical-stage pharmaceutical company, reported financial results for the quarter ended June 30, 2024. The company experienced a net loss of $6.785 million, a significant improvement from the $25.143 million loss in the same period the previous year. Basic and diluted net loss per share was $1.06, compared to $5.84 in the prior year. Revenue from product sales and royalties decreased year-on-year, with product revenue dropping from $226,000 to $64,000 and royalty revenue from $43,000 to $27,000. Operating expenses also saw a reduction, with research and development expenses decreasing by 37% to $4.15 million and general and administrative expenses by 16% to $3.314 million. The company's cash, cash equivalents, and marketable securities stood at $21.7 million as of June 30, 2024. Clene Inc. continues to focus on the development of its lead drug candidate, CNM-Au8, for central nervous system disorders. The company has no drugs approved for commercial sale and relies on revenue from dietary supplements and licensing agreements. Clene Inc. has implemented cost-saving measures and is exploring additional funding options to support its operations.
創爾新藥業，一家處於臨床階段的藥品公司，公佈了截至2024年6月30日的財務報告。公司淨虧損678.5萬美元，與前一年同期的2514.3萬美元相比有了顯著改善。基本和攤薄每股淨虧損爲1.06美元，而去年同期爲5.84美元。產品銷售和專利權利收入均同比下降，產品銷售額從226,000美元降至64,000美元，專利收入從43,000美元降至27,000美元。營業費用也有所減少，研發費用下降37%至415萬美元，管理費用下降16%至331.4萬美元。該公司截至2024年6月30日的現金、現金等價物和可供出售金融資產合計爲2170萬美元。創爾新藥業繼續專注於其治療中樞神經系統疾病的首席藥物候選品CNm-Au8的研發。該公司沒有被批准的藥品可供商業銷售，主要靠膳食補充劑和許可協議收入維持運營。創爾新藥業已實施節約成本措施並正在探索其他融資選項以支持運營。
創爾新藥業，一家處於臨床階段的藥品公司，公佈了截至2024年6月30日的財務報告。公司淨虧損678.5萬美元，與前一年同期的2514.3萬美元相比有了顯著改善。基本和攤薄每股淨虧損爲1.06美元，而去年同期爲5.84美元。產品銷售和專利權利收入均同比下降，產品銷售額從226,000美元降至64,000美元，專利收入從43,000美元降至27,000美元。營業費用也有所減少，研發費用下降37%至415萬美元，管理費用下降16%至331.4萬美元。該公司截至2024年6月30日的現金、現金等價物和可供出售金融資產合計爲2170萬美元。創爾新藥業繼續專注於其治療中樞神經系統疾病的首席藥物候選品CNm-Au8的研發。該公司沒有被批准的藥品可供商業銷售，主要靠膳食補充劑和許可協議收入維持運營。創爾新藥業已實施節約成本措施並正在探索其他融資選項以支持運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息